Shots:

• The approval is based on the P-III heiGHt trial evaluating Skytrofa (qw) vs somatropin in 161 treatment-naïve children ≥aged 1yrs. with GHD who have growth failure due to inadequate secretion of endogenous GH
• The study met its 1EPs i.e.- non-inferiority in AHV & showed a higher AHV @52wks.- no serious AEs or discontinuations related to Skytrofa were observed
• Skytrofa is the 1^st product developed by using Ascendis’ TransCon technology platform & is being evaluated in P-III trials for pediatric GHD in Japan and Greater China. The therapy will be available in the US imminently by a full suite of patient support programs

| Ref: GlobeNewswire | Image: PR Newswire